Answers are grounded in this paper and cite their sources.
To the Editor—We conducted a phase 3 trial in patients with uncomplicated urinary tract infection (UTI), comparing oral sulopenem etzadroxil + probenecid with oral ciprofloxacin [1], and we used the Food and Drug Administration's definition of overall success in studies of UTI, one that requires both clinical cure and microbiologic eradication. In the population of patients with uropathogens that were nonsusceptible to ciprofloxacin, sulopenem was superior to ciprofloxacin (62.6% vs 36.0%; difference, 26.6% [95% confidence interval (CI), 15.1%–37.4%]; P < .001). In the patients with ciprofloxacin-susceptible isolates, sulopenem was not noninferior to ciprofloxacin (66.8% vs 78.6%; difference, −11.8% [95% CI, −18.0 to −5.6). This difference could be attributed to a higher rate of asymptomatic bacteriuria after treatment in patients on sulopenem. In the analysis of all patients, sulopenem was noninferior to ciprofloxacin (65.6% vs 67.9%; difference, −2.3% [95% CI, −7.9 to 3.3]). The recent article by Howard-Anderson et al [2], describing the application of a desirability of outcome ranking (DOOR) end point to 3 trials in complicated UTI, was of considerable interest to us. After conducting DOOR analysis on our complicated UTI study [3], we have now performed a desirability of outcome ranking on our uncomplicated UTI study. We added emergence of antibiotic resistance to the DOOR components, generating a total of 6 ranks (Table 1). Desirability of Outcome Rankings by Treatment Arm One is the most desirable and 6 the least desirable ranking. Desirability of Outcome Rankings by Treatment Arm One is the most desirable and 6 the least desirable ranking. The DOOR probability that a patient in the sulopenem arm would have a more desirable outcome than a patient in the ciprofloxacin arm is 52.7% (95% CI, 50.7%–54.7%) (Figure 1), indicating that sulopenem etzadroxil + probenecid was comparably more effective than ciprofloxacin in patients with uncomplicated UTI [4]. The probabilities for the analyses prioritizing efficacy and safety were nearly identical to the original outcome ranking, and those for the individual components of absence of clinical response, infectious complications, serious adverse events, and death were very similar. The component we added, emergence of antibiotic resistance, favored sulopenem etzadroxil + probenecid. Forest plot demonstrating the desirability of outcome ranking (DOOR) probabilities for the DOOR overall, the DOOR prioritized for efficacy and safety, and the DOOR components. Abbreviations: CI, confidence interval; SAE, serious adverse event. We agree with the opinion, expressed by many at the Food and Drug Administration's June 2022 public workshop on UTI [5], that clinical trial end points should be revised to emphasize symptomatic improvement rather than microbiological eradication. For many physicians, it is standard practice to forgo follow-up urine cultures for patients whose UTI symptoms have completely resolved on antibiotics. The identification of organisms in follow-up cultures, in the form of asymptomatic bacteriuria, may result in inappropriate antibiotic use and the emergence of resistance among posttreatment flora [6]. Financial support. This work was supported by Iterum Therapeutics as a current or former full-time-employer of M. W. D., S. I. A., K. A., M. T. Z., and S. P; Iterum Therapeutics also provided consulting fees for A. F. D.
No takes yet. Share an insight, caveat, or question.
Dunne et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: